Source : https://pubmed.ncbi.nlm.nih.gov/39439440/
Patients with chronic kidney disease (CKD) have a high incidence and prevalence of atrial fibrillation (AF). While general treatment strategies for AF may largely be transferred to patients with mild...
Patients with advanced CKD and AF face treatment challenges due to high risks of both stroke and bleeding; proposed tips include novel strategies like factor XI inhibitors and left atrial appendage closure.
Source : https://pubmed.ncbi.nlm.nih.gov/38639469/
Major gaps in use of GDMT, particularly combination therapy, remain among US HFrEF patients. These gaps persist during longitudinal follow-up and are particularly large among patients with recent WHFE.
Patients with HFrEF and recent worsening heart failure events receive suboptimal guideline-directed therapy. CHART-HF reveals persistent underuse and low dosing, especially in combination treatments, across care settings.
Phase 2/3 data show tezepelumab cuts exacerbations by ~70 % across eosinophilic and non‑eosinophilic phenotypes by blocking TSLP — the master cytokine that ignites Th2 and Th17 cascades.
Could one antibody finally cover both T2‑high and T2‑low patients?
Source : https://pubmed.ncbi.nlm.nih.gov/38725148/
Strict monitoring of patients with heart failure through regular clinical examinations and drug therapies should be considered the cornerstone of national guidelines and audits.
https://pubmed.ncbi.nlm.nih.gov/38725148/
Adherence to guideline-based therapies for heart failure improves outcomes and reduces healthcare costs, supporting their inclusion in national audits and care pathways, as shown in a large Italian cohort study.
Source : https://pubmed.ncbi.nlm.nih.gov/39084827/
The novel P-WCD is a safe and effective WCD with high patient compliance. There were no deaths due to noncompliance and a high number of successful conversions (Jewel IDE study...
https://pubmed.ncbi.nlm.nih.gov/39084827/
The Jewel IDE study shows that the Jewel patch-WCD is a safe, effective, and well-tolerated wearable defibrillator with high compliance, low adverse effects, and strong performance in preventing sudden cardiac arrest.